{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:49:04Z","timestamp":1773956944711,"version":"3.50.1"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA","award":["FFP220295"],"award-info":[{"award-number":["FFP220295"]}]},{"name":"Methusalem-Centre of Excellence consortium VAX-IDEA"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chickenpox (CP) and herpes zoster (HZ), both caused by the varicella-zoster virus (VZV), present a significant public health burden in unvaccinated populations. Universal CP vaccination has been long debated due to concerns about a potential increase in HZ incidence as a consequence of the exogenous boosting hypothesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a cost-utility analysis on two deterministic compartmental dynamic transmission models, each of which employed a different underlying mechanism of exogenous boosting: temporal or progressive immunity. We considered four vaccination strategies: the current practice of no widespread vaccination and three strategies involving CP and HZ vaccination, either alone or in combination. The CP vaccines considered were Varivax and ProQuad, while the HZ vaccine considered was the recombinant zoster vaccine (RZV), Shingrix. The vaccine prices per dose were as follows: Varivax - \u20ac52.52, ProQuad - \u20ac73.69, recombinant zoster vaccine - \u20ac170.26. The clinical and economic impact of vaccination on both CP and HZ outcomes were evaluated. The main health outcome of interest was the quality-adjusted life year (QALY) which was used to compare the strategy yielding the highest average net monetary benefits (i.e., the optimal strategy) across a range of willingness-to-pay (WTP) values. Costs and health outcomes were discounted at 3.0% and 1.5% annually, respectively. We used 3 time horizons (i.e., 50, 75 &amp; 100 years) and implemented the healthcare payer perspective throughout the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CP vaccination led to a substantial reduction in CP incidence in both models. In the temporary immunity boosting (\n                      <jats:italic>Temp<\/jats:italic>\n                      ) model, strategies that included HZ vaccination showed a decrease in HZ incidence. For the CP vaccination strategy in the\n                      <jats:italic>Temp<\/jats:italic>\n                      model, and for all CP and HZ vaccination strategies in the progressive immunity boosting (\n                      <jats:italic>Prog<\/jats:italic>\n                      ) model, we observed both short- and medium-term increases in HZ, followed by a decrease to levels below the no-vaccination scenario. From the healthcare payer\u2019s perspective, using a WTP of \u20ac40,000 per QALY gained, the\n                      <jats:italic>Temp<\/jats:italic>\n                      model indicated that the three vaccination strategies were cost-effective when considering time horizons of 50, 75, and 100 years. For the\n                      <jats:italic>Prog<\/jats:italic>\n                      model, only strategies combining both CP and HZ vaccination were cost-effective given a 100-year time horizon. Vaccination strategies under the\n                      <jats:italic>Temp<\/jats:italic>\n                      model became cost-effective at lower values of WTP compared to those under the\n                      <jats:italic>Prog<\/jats:italic>\n                      model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both models predicted that universal CP vaccination would result in significant reductions in the burden of CP disease, however, the HZ disease burden impact varied significantly depending on the assumed boosting mechanism. Hence, the choice of modeled exogenous boosting mechanism leads to different optimal vaccination strategies. Ascertaining the relative accuracy of these structural model choices will require continued research on the mechanism of VZV boosting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342896","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:39:08Z","timestamp":1773941948000},"page":"e0342896","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of the impact of chickenpox and herpes zoster vaccination in Belgium under two different exogenous boosting mechanisms"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1371-0170","authenticated-orcid":true,"given":"James","family":"Wambua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Ogunjimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-0637","authenticated-orcid":true,"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-3595","authenticated-orcid":true,"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"3","key":"pone.0342896.ref001","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"AM Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"pone.0342896.ref002","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"AA Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0342896.ref003","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"MN Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"pone.0342896.ref004","volume-title":"Strategies for the control and investigation of varicella outbreaks manual","author":"AS Lopez","year":"2008"},{"issue":"2","key":"pone.0342896.ref005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/infdis\/149.2.137","article-title":"Clinical reinfection with varicella-zoster virus","volume":"149","author":"AA Gershon","year":"1984","journal-title":"J Infect Dis"},{"issue":"4","key":"pone.0342896.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114062","article-title":"Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activation","volume":"43","author":"M Boeren","year":"2024","journal-title":"Cell Reports"},{"key":"pone.0342896.ref007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1471-2334-11-173","article-title":"Herpes zoster in Germany: quantifying the burden of disease","volume":"11","author":"B Ultsch","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0342896.ref008","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1017\/S0950268811002640","article-title":"The health and economic burden of chickenpox and herpes zoster in Belgium","volume":"140","author":"J Bilcke","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"6","key":"pone.0342896.ref009","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"PM Coplan","year":"2004","journal-title":"J Pain"},{"issue":"1","key":"pone.0342896.ref010","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1186\/s12889-021-12343-x","article-title":"Economic burden of varicella in Europe in the absence of universal varicella vaccination","volume":"21","author":"M Pawaskar","year":"2021","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0342896.ref011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12879-017-2445-2","article-title":"Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization","volume":"17","author":"M Riera-Montes","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"25","key":"pone.0342896.ref012","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper","volume":"89","author":"WH Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"pone.0342896.ref013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"K Kawai","year":"2014","journal-title":"BMJ Open"},{"issue":"46","key":"pone.0342896.ref014","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1016\/j.vaccine.2018.09.013","article-title":"Herpes zoster in the context of varicella vaccination - An equation with several variables","volume":"36","author":"P Wutzler","year":"2018","journal-title":"Vaccine"},{"key":"pone.0342896.ref015","doi-asserted-by":"crossref","unstructured":"van Oorschot DAM, Vroling H, Bunge E, Briquet B, Diaz-Decaro J, Curran D. Systematic literature review of herpes zoster incidence worldwide. In: 2019.","DOI":"10.1016\/j.jval.2019.09.1347"},{"key":"pone.0342896.ref016","volume-title":"The nature of herpes zoster: a long-term study and a new hypothesis","author":"RE Hope-Simpson","year":"1965"},{"issue":"12","key":"pone.0342896.ref017","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3345\/cep.2021.01564","article-title":"Global varicella vaccination programs","volume":"65","author":"YH Lee","year":"2022","journal-title":"Clin Exp Pediatr"},{"issue":"19","key":"pone.0342896.ref018","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","article-title":"Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster","volume":"28","author":"M Brisson","year":"2010","journal-title":"Vaccine"},{"issue":"10","key":"pone.0342896.ref019","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/aje\/kws370","article-title":"Hope-Simpson\u2019s progressive immunity hypothesis as a possible explanation for herpes zoster incidence data","volume":"177","author":"G Guzzetta","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"3","key":"pone.0342896.ref020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"FH Varela","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"pone.0342896.ref021","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14760584.2018.1538801","article-title":"Understanding the role of exogenous boosting in modeling varicella vaccination","volume":"17","author":"SE Talbird","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"pone.0342896.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review","volume":"8","author":"B Ogunjimi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"pone.0342896.ref023","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41598-017-01024-8","article-title":"Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox","volume":"7","author":"B Ogunjimi","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0342896.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282327","article-title":"Systematic review of economic evaluations of varicella vaccination programmes","volume":"18","author":"R Anderson","year":"2023","journal-title":"PLoS One"},{"key":"pone.0342896.ref025","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"M Brisson","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"pone.0342896.ref026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","article-title":"The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study","volume":"16","author":"A Melegaro","year":"2018","journal-title":"BMC Med"},{"key":"pone.0342896.ref027","unstructured":"Age specific population estimates, life expectancy, and age specific prospective mortality rate data in Belgium from STATBEL (statistics Belgium). https:\/\/statbel.fgov.be\/nl"},{"issue":"1","key":"pone.0342896.ref028","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-019-1403-9","article-title":"Guidelines for multi-model comparisons of the impact of infectious disease interventions","volume":"17","author":"S den Boon","year":"2019","journal-title":"BMC Med"},{"issue":"8","key":"pone.0342896.ref029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/aje\/kwv240","article-title":"The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling","volume":"183","author":"G Guzzetta","year":"2016","journal-title":"Am J Epidemiol"},{"key":"pone.0342896.ref030","unstructured":"Belgian Center for Pharmacotherapeutic Information. Vaccine against zona. https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=20636. 2023. 2023 March 21."},{"key":"pone.0342896.ref031","unstructured":"The General Practitioner: Price Consultations in Belgium in 2023. https:\/\/www.cm.be\/diensten-en-voordelen\/ziekte-en-behandeling\/terugbetalingen-behandelingen\/huisartsen\/raadplegingen 2023 March 21."},{"issue":"6","key":"pone.0342896.ref032","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S0266462314000725","article-title":"Belgian guidelines for economic evaluations","volume":"30","author":"N Thiry","year":"2014","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"4","key":"pone.0342896.ref033","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0272989X211045070","article-title":"Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice","volume":"42","author":"J Bilcke","year":"2022","journal-title":"Med Decis Making"},{"key":"pone.0342896.ref034","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015"},{"key":"pone.0342896.ref035","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac251","article-title":"25 Years of Varicella Vaccination in the United States","volume":"226","author":"M Marin","year":"2022","journal-title":"J Infect Dis"},{"issue":"9","key":"pone.0342896.ref036","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14760584.2020.1825947","article-title":"Varicella vaccination in Italy and Germany - different routes to success: a systematic review","volume":"19","author":"F Kauffmann","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"pone.0342896.ref037","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4161\/hv.34311","article-title":"Impact of universal vaccination against varicella in Italy: experiences from eight Italian regions","volume":"11","author":"A Bechini","year":"2015","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"2","key":"pone.0342896.ref038","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/vaccines11020306","article-title":"Sero-Epidemiological Study of Varicella in the Italian General Population","volume":"11","author":"G Gabutti","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"pone.0342896.ref039","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.vaccine.2013.11.008","article-title":"Different vaccination strategies in Spain and its impact on severe varicella and zoster","volume":"32","author":"R Gil-Prieto","year":"2014","journal-title":"Vaccine"},{"issue":"42","key":"pone.0342896.ref040","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1016\/j.vaccine.2013.08.022","article-title":"The impact of the universal infant varicella immunization strategy on Canadian varicella-related hospitalization rates","volume":"31","author":"A Waye","year":"2013","journal-title":"Vaccine"},{"issue":"50","key":"pone.0342896.ref041","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1016\/j.vaccine.2023.11.015","article-title":"Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia","volume":"41","author":"AC Shrestha","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"pone.0342896.ref042","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4161\/hv.23334","article-title":"Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?","volume":"9","author":"J Bilcke","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"pone.0342896.ref043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176845","article-title":"The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster","volume":"12","author":"L Marangi","year":"2017","journal-title":"PLoS One"},{"issue":"13","key":"pone.0342896.ref044","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"AJ van Hoek","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"pone.0342896.ref045","article-title":"Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom","volume":"73","author":"EIH Akpo","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0342896.ref046","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/vaccines10091416","article-title":"Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales","volume":"10","author":"O Sharomi","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1804","key":"pone.0342896.ref047","first-page":"20142509","article-title":"The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study","volume":"282","author":"V Marziano","year":"2015","journal-title":"Proc Biol Sci"},{"issue":"6","key":"pone.0342896.ref048","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bulm.1999.0126","article-title":"Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles","volume":"61","author":"MC Schuette","year":"1999","journal-title":"Bull Math Biol"},{"issue":"2","key":"pone.0342896.ref049","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.vaccine.2023.12.045","article-title":"Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review","volume":"42","author":"Z Jordan","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"pone.0342896.ref050","first-page":"118","article-title":"Knowledge, attitude and vaccination status of varicella among students of Universiti Kebangsaan Malaysia (UKM)","volume":"64","author":"R Hesham","year":"2009","journal-title":"Med J Malaysia"},{"issue":"10","key":"pone.0342896.ref051","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ebiom.2015.08.017","article-title":"Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster","volume":"2","author":"A van Lier","year":"2015","journal-title":"EBioMedicine"},{"issue":"8","key":"pone.0342896.ref052","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.vaccine.2018.01.038","article-title":"Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway","volume":"36","author":"S Marchetti","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"pone.0342896.ref053","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"M Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"key":"pone.0342896.ref054","article-title":"Risk of herpes zoster in adults immunized with varicella vaccine","author":"S Hambleton","year":"2008","journal-title":"J Infect Dis"},{"issue":"11","key":"pone.0342896.ref055","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"R Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"pone.0342896.ref056","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","article-title":"The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013","volume":"73","author":"PHF Hobbelen","year":"2016","journal-title":"J Infect"},{"issue":"9","key":"pone.0342896.ref057","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.vaccine.2021.01.061","article-title":"Modelling a cost-effective vaccination strategy for the prevention of varicella and herpes zoster infection: A systematic review","volume":"39","author":"B Hodgkinson","year":"2021","journal-title":"Vaccine"},{"key":"pone.0342896.ref058","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiac255","article-title":"The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch","volume":"226","author":"J Leung","year":"2022","journal-title":"J Infect Dis"},{"key":"pone.0342896.ref059","article-title":"Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data","volume":"368","author":"H Forbes","year":"2020","journal-title":"BMJ"},{"key":"pone.0342896.ref060","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.07116","article-title":"Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster","volume":"4","author":"B Ogunjimi","year":"2015","journal-title":"Elife"},{"issue":"8","key":"pone.0342896.ref061","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciy1099","article-title":"Systematic Review and Meta-analysis of Chickenpox Vaccination and Risk of Herpes Zoster: A Quantitative View on the \u201cExogenous Boosting Hypothesis\u201d","volume":"69","author":"T Harder","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0342896.ref062","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study","volume":"63","author":"K Kawai","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0342896.ref063","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"J Leung","year":"2011","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"pone.0342896.ref064","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1080\/21645515.2018.1446718","article-title":"Trends in herpes zoster epidemiology in Germany based on primary care sentinel surveillance data, 2005\u20132016","volume":"14","author":"B Zoch-Lesniak","year":"2018","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3","key":"pone.0342896.ref065","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s13555-021-00535-7","article-title":"Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007\u20132018","volume":"11","author":"M Batram","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"4","key":"pone.0342896.ref066","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jinf.2022.01.003","article-title":"Incidence of complications of herpes zoster in individuals on immunosuppressive therapy: A register-based population study","volume":"84","author":"S Chawki","year":"2022","journal-title":"J Infect"},{"key":"pone.0342896.ref067","doi-asserted-by":"crossref","first-page":"100778","DOI":"10.1016\/j.epidem.2024.100778","article-title":"Social contact patterns following the COVID-19 pandemic: a snapshot of post-pandemic behaviour from the CoMix study","volume":"48","author":"CI Jarvis","year":"2024","journal-title":"Epidemics"},{"issue":"52","key":"pone.0342896.ref068","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1016\/j.vaccine.2014.10.015","article-title":"Varicella-zoster virus vaccination under the exogenous boosting hypothesis: two ethical perspectives","volume":"32","author":"J Luyten","year":"2014","journal-title":"Vaccine"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:39:16Z","timestamp":1773941956000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342896"}},"subtitle":[],"editor":[{"given":"Georges M.G.M.","family":"Verjans","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342896","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}